Greenbrook TMS Inc.
greenbrooktms.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2024 10-Q, filed Aug 14, 2024. Its latest SEC filing is a 15-12G from Dec 10, 2024.
10-Q for Q2 FY2024, filed Aug 14, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Runs outpatient centers that provide magnetic stimulation therapy and Spravato nasal-spray treatment to people with depression and other mental health disorders.
10-K for FY2023, filed Apr 26, 2024
How Did They Make Money?
Greenbrook earns fees for patient services paid by government health programs, managed-care plans and commercial insurers; the fees are counted when it performs the services.
10-K for FY2023, filed Apr 26, 2024Service fee revenue is recognized at a point in time upon the performance of services under contracts with customers and represents the…View ↗
$24.6M
-
10-K for FY2023, filed Apr 25, 2024
$24.6M ↗
Who Were Their Customers?
Patients receive treatment at Greenbrook’s centers, with service fees paid through federal and state health programs, managed-care plans, and commercial insurers.
10-K for FY2023, filed Apr 26, 2024
Did Revenues Turn Into Profits?
No. It lost $48.9M in FY2023.
10-K for FY2023, filed Apr 25, 2024
−$32.8MView ↗
10-K for FY2023, filed Apr 25, 2024
−$48.9MView ↗
10-K for FY2023, filed Apr 25, 2024
−$35.9MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2024, filed Aug 13, 2024
−$12.4MView ↗
- ▼ −3% (Loss)
- vs −$12.7M in Q2 FY2023
-
Dec 10, 2024
Neuronetics acquired Greenbrook in an all-stock transaction
Greenbrook became an indirect, wholly owned subsidiary of Neuronetics after the arrangement closed.
Sources
8-K, filed Dec 10, 2024
Effective as of December 9, 2024, the Company and Neuronetics, Inc. (“Neuronetics”) completed the previously announced transaction pursuant…View ↗
Loading...
